Maintenance immunotherapy in advanced urothelial cancer
Advanced urothelial carcinoma usually responds to platinum-based chemotherapy (CT), although overall survival (OS) and progression-free survival are typically short. Immunotherapy is a promising treatment strategy, but the first-line benefits in platinum-eligible patients are limited, and its combin...
I tiakina i:
| Ngā kaituhi matua: | , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Permanyer
2022-07-01
|
| Rangatū: | Gaceta Mexicana de Oncología |
| Ngā marau: | |
| Urunga tuihono: | https://www.gamo-smeo.com/frame_esp.php?id=323 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
